Skip to main content

Advertisement

Table 3 Worm distribution in the hepatic and portomesenteric vessels of S. mansoni-infected treated mice

From: A novel praziquantel solid lipid nanoparticle formulation shows enhanced bioavailability and antischistosomal efficacy against murine S. mansoni infection

Dose (mg/kg) Animal group Total no. of worms Total no. of male worms Total no. of female worms Total no. of hepatic worms Total no. of portomesenteric worms
Control 21.00 ± 0.59 12.44 ± 1.6 8.56 ± 1.0 5.33 ± 1.14 15.66 ± 1.98
62.5 M-PZQ 10.17 ± 0.4 (51.59)* 6.33 ± 1.0 (49.09)* 3.83 ± 0.7 (55.22)* 4.66 ± 0.8 5.5 ± 0.62*
SLN-PZQ 2.83 ± 0.7 (86.51)* 2.67 ± 0.7 (78.56)* 0.17 ± 0.1 (98.05)* 1.00 ± 0.26* 1.83 ± 0.60*
125 M-PZQ 5.83 ± 0.7 (72.22)* 3.83 ± 1.0 (69.19)* 1.33 ± 0.2 (84.42)* 2.83 ± 0.98* 2.33 ± 0.76*
SLN-PZQ 1.17 ± 0.4 (94.44)* 0.83 ± 0.3 (92.50)* 0.33 ± 0.2 (95.33)* 0.33 ± 0.21*$ 0.83 ± 0.98*
250 M-PZQ 2.29 ± 0.1 (89.10)* 2.0 ± 0.2 (83.92)* 0.29 ± 0.1 (96.66)* 0.57 ± 0.4* 0.57 ± 0.20*
SLN-PZQ 0.83 ± 0.3 (96.05)* 0.67 ± 0.2 (94.64)* 0.17 ± 0.1 (98.05)* 0.33 ± 0.5* 0.33 ± 0.20*
500 M-PZQ 1.43 ± 0.2 (93.19)* 0.86 ± 0.3 (93.11)* 0.57 ± 0.2 (93.32)* 1.17 ± 0.38* 0.29 ± 0.49*
SLN-PZQ 0.50 ± 0.3 (97.62)* 0.33 ± 0.3 (97.32)* 0.33 ± 0.2 (98.05)* 0.5 ± 0.34* 0.00 ± 0.00*
1000 M-PZQ 0.75 ± 0.3 (96.43)* 0.63 ± 0.3 (94.98)* 0.13 ± 0.1 (98.54)* 0.75 ± 0.31* 0.00 ± 0.00*
SLN-PZQ 0.33 ± 0.2 (98.43)* 0.33 ± 0.2 (97.32)* 0.00 ± 0.0 (100.0)* 0.17 ± 0.16* 0.16 ± 0.16*
  1. Notes: Data are presented as the means ± SEM. n = 6–8 mice per group. Mice were sacrificed 14 days after treatment. Number in parentheses represents the percentage worm reduction versus the infected untreated control. Percentage of worm reduction = (mean number of worms in control group - mean number of worms in treated group)/mean number in control group × 100
  2. * Significant differences of SLN-PZQ or M-PZQ versus parallel infected untreated control at P < 0.05
  3. Significant differences of SLN-PZQ versus parallel values of M-PZQ at P < 0.05
  4. Abbreviations: SLN-PZQ, solid lipid nanoparticle praziquantel; M-PZQ, market praziquantel